Abstract
The appeal of using embryonic stem (ES) cells for regenerative medicine lies in their pluripotency and resulting ability to differentiate into all somatic cell types. While graft rejection remains the greatest hurdle to their use in the clinic, several approaches have been proposed to protect the allogeneic ES cell-derived grafts from host immunity: the creation of nuclear transfer human ES (hES) cell lines; the development of parthenogenic hES cells and iPS cells; the establishment of a bank of clinically-approved lines; the generation of hematopoietic chimerism and the induction of peripheral tolerance in recipients. Here, we discuss how the immune-privileged features of ES cells and tissues derived from them may influence these approaches and review the strategies and mechanisms involved in sustaining antigen-specific tolerance through interplay between dendritic cells (DC) and regulatory T cells (Treg). This overview therefore surveys prospects for developing novel regimes to prolong acceptance of ES cell-derived tissues with minimal use of immunosuppressive drugs.
Keywords: Embryonic stem cells, immune privilege, transplantation
Current Stem Cell Research & Therapy
Title: Embryonic Stem Cells: Overcoming the Immunological Barriers to Cell Replacement Therapy
Volume: 4 Issue: 1
Author(s): Kathy O. Lui, Herman Waldmann and Paul J. Fairchild
Affiliation:
Keywords: Embryonic stem cells, immune privilege, transplantation
Abstract: The appeal of using embryonic stem (ES) cells for regenerative medicine lies in their pluripotency and resulting ability to differentiate into all somatic cell types. While graft rejection remains the greatest hurdle to their use in the clinic, several approaches have been proposed to protect the allogeneic ES cell-derived grafts from host immunity: the creation of nuclear transfer human ES (hES) cell lines; the development of parthenogenic hES cells and iPS cells; the establishment of a bank of clinically-approved lines; the generation of hematopoietic chimerism and the induction of peripheral tolerance in recipients. Here, we discuss how the immune-privileged features of ES cells and tissues derived from them may influence these approaches and review the strategies and mechanisms involved in sustaining antigen-specific tolerance through interplay between dendritic cells (DC) and regulatory T cells (Treg). This overview therefore surveys prospects for developing novel regimes to prolong acceptance of ES cell-derived tissues with minimal use of immunosuppressive drugs.
Export Options
About this article
Cite this article as:
Lui O. Kathy, Waldmann Herman and Fairchild J. Paul, Embryonic Stem Cells: Overcoming the Immunological Barriers to Cell Replacement Therapy, Current Stem Cell Research & Therapy 2009; 4 (1) . https://dx.doi.org/10.2174/157488809787169093
DOI https://dx.doi.org/10.2174/157488809787169093 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of microRNAs in the Pathogenesis and Treatment of Hematopoietic Malignancies
Current Pharmaceutical Design CD44 and its Role in Inflammation and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Localised Delivery of Therapeutic Agents to CNS Malignancies: Old and New Approaches
Current Pharmaceutical Biotechnology Development of Nucleic Acid Drugs for Neurological Disorders
Current Topics in Medicinal Chemistry Mechanisms of CTLA-4-Ig in Tolerance Induction
Current Pharmaceutical Design Neurotrophic Factors in Combination: A Possible new Therapeutic Strategy to Influence Pathophysiology of Spinal Cord Injury and Repair Mechanisms
Current Pharmaceutical Design Nanoparticle- and Liposome-carried Drugs: New Strategies for Active Targeting and Drug Delivery Across Blood-brain Barrier
Current Drug Metabolism Natural Naphthoquinones with Great Importance in Medicinal Chemistry
Current Organic Synthesis Integrin α4β7 Antagonists: Activities, Mechanisms of Action and Therapeutic Prospects
Current Immunology Reviews (Discontinued) Update on Targets of Biologic Therapies for Rheumatoid Arthritis
Current Rheumatology Reviews Contribution of Spinal Cord Oligodendrocytes to Neuroinflammatory Diseases and Pain
Current Medicinal Chemistry Oral Tolerance and TGF-β -Producing Cells
Inflammation & Allergy - Drug Targets (Discontinued) Autoimmune Diseases and Atherosclerosis: The Inflammatory Connection
Current Immunology Reviews (Discontinued) A Systems Biology Approach for miRNA-mRNA Expression Patterns Analysis in Rheumatoid Arthritis
Combinatorial Chemistry & High Throughput Screening Multiple Sclerosis – Established and Novel Therapeutic Approaches
Central Nervous System Agents in Medicinal Chemistry Metformin, A New Era for an Old Drug in the Treatment of Immune Mediated Disease?
Current Drug Targets Cross-Talk Between NO Synthase Isoforms in Neuro-Inflammation: Possible Implications in HIV-Associated Neurocognitive Disorders
Current Medicinal Chemistry Mechanisms of Control of Neuron Survival by the Endocannabinoid System
Current Pharmaceutical Design Glycolipid Stimulators for NKT Cells Bearing Invariant Vα19-Jα33 TCR α Chains
Mini-Reviews in Medicinal Chemistry Mast Cells and Inflammatory Heart Disease: Potential Drug Targets
Cardiovascular & Hematological Disorders-Drug Targets